针对白血病中Menin-KMT2A相互作用:经验教训和未来方向
Florian Perner1,2, Jayant Y Gadrey3, Scott A Armstrong4
1Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
International journal of cancer
|January 31, 2025
概括
染色体重组涉及混合血统白血病基因 (KMT2A) 驱动急性白血病的一个子集. 门-KMT2A抑制剂对向治疗具有前景,其中一种药物已批准用于特定类型的白血病.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- KMT2A重组定义了急性白血病的一个子集,通常与预后不佳有关.
- 非重新排列的KMT2A复合体也在白血病的发展中起作用.
研究的目的:
- 审查KMT2A在癌症中的生物学,专注于白血病.
- 提供针对KMT2A.的Menin抑制剂的临床和临床前研究概述.
主要方法:
- 对KMT2A生物学和Menin抑制剂研究的文献综述.
- 对临床前模型和早期临床试验数据的分析.
主要成果:
- KMT2A融合产生致癌蛋白质,而KMT2A复合体在其他白血病中至关重要.
- 门宁-KMT2A抑制剂在临床前和临床环境中显示出有效性.
- 作为Menin抑制剂的Revumenib已被批准用于KMT2A重组的急性白血病.
结论:
- 针对Menin-KMT2A相互作用是KMT2A驱动的白血病的可行治疗策略.
- 了解耐药机制对于优化单剂或组合疗法至关重要.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


